Abstract: Systems and methods for entity recommendation can make use of rich data by allowing the items to be recommended and the recipients of the recommendation (e.g., users) to be modeled as “complex entities” composed of one or more static sub-entities and/or a dynamic component, and by utilizing information about multiple relationships between the sub-entities as reflected in bipartite graphs. Generating recommendations from such information may involve creating vector representations of the sub-entities based on the bipartite graphs (e.g., using graph-based convolutional networks), and combining these vector representations into representations of the items and users (or other recipients) to be fed into a classifier model.

Abstract: Systems and methods for entity recommendation can make use of rich data by allowing the items to be recommended and the recipients of the recommendation (e.g., users) to be modeled as “complex entities” composed of one or more static sub-entities and/or a dynamic component, and by utilizing information about multiple relationships between the sub-entities as reflected in bipartite graphs. Generating recommendations from such information may involve creating vector representations of the sub-entities based on the bipartite graphs (e.g., using graph-based convolutional networks), and combining these vector representations into representations of the items and users (or other recipients) to be fed into a classifier model.

Abstract: Systems and methods for entity recommendation can make use of rich data by allowing the items to be recommended and the recipients of the recommendation (e.g., users) to be modeled as “complex entities” composed of one or more static sub-entities and/or a dynamic component, and by utilizing information about multiple relationships between the sub-entities as reflected in bipartite graphs. Generating recommendations from such information may involve creating vector representations of the sub-entities based on the bipartite graphs (e.g., using graph-based convolutional networks), and combining these vector representations into representations of the items and users (or other recipients) to be fed into a classifier model.

Abstract: Systems and methods for entity recommendation can make use of rich data by allowing the items to be recommended and the recipients of the recommendation (e.g., users) to be modeled as “complex entities” composed of one or more static sub-entities and/or a dynamic component, and by utilizing information about multiple relationships between the sub-entities as reflected in bipartite graphs. Generating recommendations from such information may involve creating vector representations of the sub-entities based on the bipartite graphs (e.g., using graph-based convolutional networks), and combining these vector representations into representations of the items and users (or other recipients) to be fed into a classifier model.

Abstract: The present invention relates to ?1, and/or ?1d adrenergic receptor antagonists, which can function as ?1a and/or ?1d adrenergic receptor antagonist and can be used for the treatment of a disease or disorder mediated through ?1a and/or an adrenergic receptor. Compounds disclosed herein can be used for the treatment of benign prostatic hyperplasia (BPH) and the related symptoms thereof. Further, compounds disclosed herein can be used for the treatment of lower urinary tract symptoms associated with or without BPH. Also provided are processes for preparing such compounds, pharmaceutical compositions thereof, and the methods of treating BPH or related symptoms thereof.

Abstract: This invention relates to ?1a and/or ?1d adrenergic receptor antagonists of formula 1 Compounds disclosed herein can function as ?1a and/or ?1d adrenergic receptor antagonists and can be used for the treatment of diseases or disorders mediated through ?1a and/or ?1d adrenergic receptors. Compounds disclosed herein can be used for the treatment of benign prostatic hyperplasia and related symptoms thereof. Compounds disclosed herein can also be used for the treatment of lower urinary tract symptoms associated with or without benign prostatic hyperplasia. The invention also relates to a process for the preparation of compounds disclosed herein, pharmaceutical compositions containing these compounds and the methods of treating diseases or disorders mediated through ?1a and/or ?1d receptors.